MetaCap

Filana Therapeutics (FLNA) vs GridAI Technologies (GRDX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GridAI Technologies (GRDX) has outperformed Filana Therapeutics (FLNA) over the past year, gaining 20.6% versus a loss of 77.7%. Over five years, FLNA leads with a -98.9% price change compared with -100.0% for GRDX. GridAI Technologies is the larger company by market cap ($32.4 million vs $32.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FLNA-77.66%GRDX+20.61%
+172%+37%-97%
Nov 21, 20251 yearNov 20, 2026
FLNA-98.79%GRDX-99.99%
+10%-47%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FLNA versus GRDX key metrics
MetricFLNAGRDX
Share price$0.6413$3.16
Market cap$32.26M$32.44M
1-day change+14.52%-8.41%
YTD return-67.61%-32.19%
1-year return-77.66%+20.61%
5-year return-98.85%-99.99%
EPS (TTM)$-0.87$-5.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$36.25K
Net income (latest FY)$-90.97M$-6.39M
Gross margin—-1813.56%
Operating margin—-19539.98%
Net margin—-17634.42%
52-week high$3.45$6.93
52-week low$0.39$1.87
Distance from 52-week high-81.41%-54.39%
Analyst consensusnone—
Avg. price target upside+913.57%—
Average volume2.09M120.78K
Shares outstanding50.30M10.27M
Employees17—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GRDX has outperformed FLNA by 98.3 percentage points over the past year.

About Filana Therapeutics

FLNA stock →

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About GridAI Technologies

GRDX stock →

GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.

Health Care · Biotechnology: Pharmaceutical Preparations

FLNA vs GRDX FAQ

Which is bigger, Filana Therapeutics or GridAI Technologies?

GridAI Technologies (GRDX) is larger, with a market capitalization of $32.44M compared with $32.26M for Filana Therapeutics (FLNA).

Which stock has performed better over the past year, FLNA or GRDX?

GRDX returned +20.61% over the past 12 months, compared with -77.66% for FLNA (price return, excluding dividends). Past performance does not predict future results.

Are Filana Therapeutics and GridAI Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons